Clinical Trials Browser

Phase 1/2 × Recruiting × Endocrine × Clear all

NCT06607692 2026-04-14

LUPARPED

Phase 1/2 Recruiting

CNSEndocrineNETSarcoma

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma, Pheochromocytoma, Recurrence, Osteosarcoma, Sarcoma, Synovial, Esthesioneuroblastoma, Olfactory, Neuroendocrine Tumors

NCT05048901 2026-04-09

Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

Phase 1/2 Recruiting

Neuroendocrine Tumors

NCT07278479 2026-04-08

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

Phase 1/2 Recruiting

EndocrineThoracic

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT04086485 2026-04-07

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

Phase 1/2 Recruiting

Carcinoid Tumor, Neuroendocrine Tumors

NCT03093116 2026-04-03

TRIDENT-1

Phase 1/2 Recruiting

500 enrolled 5 FDA

EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colonic Neoplasms, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Neuroectodermal Tumors, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT06427798 2026-03-10

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

Phase 1/2 Recruiting

Paraganglioma, Pheochromocytoma

NCT07129252 2026-03-10

BRAVESST2

Phase 1/2 Recruiting

Neoplasm Metastasis, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT06542237 2026-02-13

Open Label, Dose Escalation, Repeat Dose Study Evaluating YCT-529 in Healthy Males

Phase 1/2 Recruiting

Multiple Endocrine Neoplasia Type 1

NCT06055439 2026-01-29

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

Phase 1/2 Recruiting

EndocrineGastrointestinalNET

Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors

NCT07174583 2026-01-23

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

Phase 1/2 Recruiting

EndocrineThoracic

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT05978284 2026-01-05

Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

Phase 1/2 Recruiting

EndocrineThoracic

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT07038096 2026-01-05

ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

Phase 1/2 Recruiting

EndocrineThoracic

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT06943521 2025-12-11

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Phase 1/2 Recruiting

BreastEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Endometrial Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05636618 2025-11-24

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors

Phase 1/2 Recruiting

CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT06283719 2025-11-17

Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer

Phase 1/2 Recruiting

EndocrineThoracic

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT05652686 2025-09-23

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Phase 1/2 Recruiting

EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT05944237 2025-06-08

HTL0039732 in Participants With Advanced Solid Tumours

Phase 1/2 Recruiting

EndocrineGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Pheochromocytoma, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06455358 2025-05-30

61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)

Phase 1/2 Recruiting

Neuroendocrine Tumors

NCT03145857 2025-05-14

A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use

Phase 1/2 Recruiting

Neuroendocrine Tumors

NCT05804669 2025-04-10

A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome

Phase 1/2 Recruiting

ACTH Syndrome, Ectopic, Cushing Syndrome, Pituitary ACTH Hypersecretion

NCT06056362 2025-04-02

Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors

Phase 1/2 Recruiting

Neuroendocrine Tumors

NCT06440057 2024-12-16

Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.

Phase 1/2 Recruiting

Carcinoma, Neuroendocrine

NCT02174549 2024-11-22

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Phase 1/2 Recruiting

EndocrineGastrointestinalNET

Hypoxia, Carcinoma, Hepatocellular, Neuroendocrine Tumors

NCT06038461 2024-10-01

An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors

Phase 1/2 Recruiting

Neuroendocrine Tumors

NCT06372626 2024-06-14

Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.

Phase 1/2 Recruiting

Carcinoma, Neuroendocrine